Peptide blends: what sharing a vial does to testing and stability

What a blend is, and what the catalogue lists

Nothing joins the peptides in a blend chemically, which separates it from a single molecule built to act at more than one receptor.

The store lists four blends as vials. The table gives what each listing stated on 8 October 2026.

For Glow the table gives only the vial size, because the listing’s figures for the three components add up to more than 70 mg.

Two names in the table need care. “TB-500” has been used for more than one molecule, as the rat study below shows, and the “(no DAC)” in the second listing marks one of two forms of CJC-1295. The TB-500 and CJC-1295 pages explain both.

Why combinations are studied

Human study One reason is that two compounds may act through different pathways. In a 1990 study in 18 healthy men, a synthetic growth hormone-releasing peptide released growth hormone, and together with the hormone GHRH it did so synergistically.⁴ The authors took this to suggest that the two act independently.⁴ That result belongs to those two compounds, not to CJC-1295 and ipamorelin, which their own pages place with the GHRH analogues and the growth hormone secretagogues.

Review A 2026 narrative review described its findings on CJC-1295 with ipamorelin as limited to animal studies.⁵ The ipamorelin page examines the experiment behind that statement.

Animal study A second reason is to test whether effects add up. A 2026 study cut and repaired the Achilles tendon in 32 rats and assigned them at random to control, BPC-157, TB-500 or both.¹ At four weeks the combination had conferred nothing beyond either peptide alone, and the authors called the work exploratory.¹ The abstract describes its TB-500 as synthetic thymosin beta-4, and does not say whether the two peptides were mixed in one solution.¹

A blend also fixes the ratio. An experiment that needs to vary one component, or to leave one out as a control, needs the single compounds.

What a blend does to analysis

Every component has to be found

The international guideline on validating analytical procedures asks that the identification or measurement of a substance be unaffected by other components likely to be present.⁶ Where one procedure cannot discriminate, it recommends combining two or more.⁶ In a blend, the other peptides are exactly such components.

Chemistry study A Belgian medicines control laboratory has described such a method: a 30-minute screen, by liquid chromatography with tandem mass spectrometry, that selectively detects 25 peptides, followed by quantification with diode array detection.⁷

Peaks can overlap

A purity figure is normally the area of the main peak on an HPLC trace as a share of all the peaks, as the guide to analytical methods for peptides explains. A blend has several main peaks, and an impurity from one component can sit under the peak of another. For a critical separation, the guideline’s test is the resolution of the two components that elute closest together.⁶

Chemistry study The components may also behave very differently on the column. Small, very hydrophilic peptides are poorly retained on conventional reversed-phase columns,⁸ and a formulation study measured the GHK-copper complex as highly hydrophilic.⁹ Glow and Klow put that complex beside longer chains. Where peaks cannot be pulled apart, high-resolution mass spectrometry can quantify impurities even when they co-elute.¹⁰

Content: milligrams and molecules

Chemistry study Peak areas do not convert directly into amounts. Measured at 214 nm, tryptophan absorbs about 30 times as strongly as a peptide bond, and phenylalanine, tyrosine and histidine about six times.¹¹ Two peptides present in equal amounts can therefore give unequal peaks, and each needs its own calibration.

Mass and molecule count diverge as well. With PubChem’s molecular weights, the stated Klow contents work out as follows, if each stated mass were entirely the named compound.

The last two rows differ more than fivefold. The identity behind a name has to be settled before any arithmetic.

What a blend does to stability

Chemistry study Each component brings its own chemistry. In stress tests, the GHK-copper complex was susceptible to cleavage under basic and oxidative conditions, and less so under acid, yet stable in water and in buffers from pH 4.5 to 7.4 for at least two weeks at 60 °C.⁹ KPV under acid, alkali or peroxide stress gave a diketopiperazine, a small ring formed from its first two residues, as the main degradation product.¹⁷

Chemistry study Rates differ too. When a doping-control laboratory stored 54 compounds in serum and plasma at 4 and 22 °C, several peptides were extensively degraded after one week in both, while BPC-157 and TB-500 were completely degraded only in serum.¹⁸ All were stable for at least two months at −20 °C.¹⁸ Those were blood samples, not vials, but they show that peptides in one liquid need not last equally long.

Chemistry study Components can also act on each other. In a co-formulation study, insulin and pramlintide, an analogue of the hormone amylin, formed mixed pairs.¹⁹ At pH 7.0 the pairing did not prevent aggregation of pramlintide, and at pH 5.0 pramlintide with fast-acting insulin analogues was stable against it.¹⁹

Review A review of peptide aggregation lists sequence, concentration, pH, net charge, excipients (added ingredients) and impurities among the factors that influence physical stability.²⁰ In a blend, each peptide is in effect part of the others’ formulation.

Chemistry study Glow and Klow add a metal. In one study the GHK-copper complex was inert under moderate redox conditions, meaning that it did not readily gain or lose electrons, and copper exchanged quickly between GHK peptides.²¹ The searches described below found no study of how the complex behaves alongside BPC-157, TB-500 or KPV.³

Stability data for a single compound therefore cannot be assumed to hold for a blend that contains it. The guide to peptide stability and degradation covers the routes involved.

Where the published literature is

PubMed was searched on 8 October 2026 for records naming the components together.

• BPC-157 with TB-500 or thymosin beta. Twelve records: nine reviews, one analytical method, the rat study above and one retrospective chart review.²²
• CJC-1295 with ipamorelin. Ten records: nine reviews and one method for detecting peptides in horse plasma.²
• GHK-Cu with BPC-157, TB-500 or KPV. Eight records, all of them reviews.³

The compound pages report the experiments on each peptide alone.

Human evidence

Human study The only human record these searches found is a retrospective review of patient charts from one clinic.²³ Of 16 patients reached by telephone, 12 had received BPC-157 and four had received it with thymosin beta-4; three of those four reported less knee pain afterwards.²³ The abstract describes no comparison group and says that no specific tool was used to measure function, so the report cannot show what either peptide did.²³

ClinicalTrials.gov, searched on the same date, returned no registered study of any of the four combinations.²⁴ These sources hold no controlled human study of any blend listed here. Products on this site are supplied for laboratory research use only.